Synthomer and Spyre Therapeutics stocks rise above key moving averages amid analyst upgrades

Synthomer plc (LON:SYNT) broke above its 200‑day moving average on Friday, trading as high as GBX 84.22 and closing at GBX 82. Analysts lifted their price targets, with Jefferies setting a GBX 65 objective and Berenberg raising its target to GBX 100. The consensus target now sits at GBX 86.75. The company reported quarterly earnings of GBX 91.90 per share and maintains a market cap of £134.43 million. Insider Lily Liu purchased 29,192 shares at an average price of GBX 66.

Spyre Therapeutics, Inc. (NASDAQ:SYRE) climbed 5.7% on Friday, reaching $99.45, above its 200‑day simple moving average of $57.90. Analysts upgraded their forecasts, with Mizuho raising the target to $120 (outperform), Jefferies to $85 (buy), BTIG to $112 (buy), and Citigroup to $97 (buy). The consensus price target is $101.42 and the stock holds a "moderate buy" rating. The firm posted a quarterly loss of $0.74 per share. CFO Scott L. Burrows sold 15,000 shares at $87.13.